Sugi Predict

Sugi Predict / Compounds / SCHEMBL1471503

SCHEMBL1471503

SCHEMBL1471503

NC(=NS(=O)(=O)c1cc(Cl)c(Oc2ccc([N+](=O)[O-])cc2)c(Cl)c1)c1ccncc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ LMNA P02545 1/20 0.51
▸ KMT2A Q03164 2/20 0.47
▸ PKM P14618 1/20 0.47
▸ NPC1 O15118 1/20 0.45
▸ F2 P00734 4/20 0.43
▸ PRSS1 P07477 4/20 0.43
▸ PRSS2 P07478 4/20 0.43
▸ PRSS3 P35030 4/20 0.43
▸ GAA P10253 2/20 0.40
▸ MMP13 P45452 1/20 0.39
▸ THRA P10827 3/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471814 0.90 ALDH1A1 (0.56) MAPTALDH1A1SMN1; SMN2LMNAF2
SCHEMBL5798194 0.90 SMN1; SMN2 (0.62) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL1472081 0.88 MAPT (0.50) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL1471217 0.88 THRA (0.52) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL1471998 0.83 F2 (0.50) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL1471421 0.81 F2 (0.47) ALDH1A1SMN1; SMN2LMNAF2PRSS1
SCHEMBL1471502 0.78 GAA (0.44) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5779046 0.78 THRA (0.56) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL6363615 0.78 ALDH1A1 (0.57) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL1472255 0.77 THRA (0.50) MAPTALDH1A1SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US claimed
EP-1651595-A2 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2006-05-03 — — EP claimed
WO-2005007621-A2 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-01-27 — — WO claimed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 — — US claimed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A MAPT 1796/4885ALDH1A1 1362/4885SMN1; SMN2 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.